- Home
- SAGE vs DNA Comparison
SAGE vs DNA Comparison
Compare SAGE & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAGE
- DNA
- Stock Information
- Founded
- SAGE 2010
- DNA 2008
- Country
- SAGE United States
- DNA United States
- Employees
- SAGE N/A
- DNA N/A
- Industry
- SAGE Biotechnology: Pharmaceutical Preparations
- DNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SAGE Health Care
- DNA Health Care
- Exchange
- SAGE Nasdaq
- DNA Nasdaq
- Market Cap
- SAGE 474.6M
- DNA 562.1M
- IPO Year
- SAGE 2014
- DNA N/A
- Fundamental
- Price
- SAGE $7.37
- DNA $5.70
- Analyst Decision
- SAGE Hold
- DNA Sell
- Analyst Count
- SAGE 19
- DNA 5
- Target Price
- SAGE $9.88
- DNA $17.25
- AVG Volume (30 Days)
- SAGE 1.2M
- DNA 1.3M
- Earning Date
- SAGE 04-24-2025
- DNA 05-08-2025
- Dividend Yield
- SAGE N/A
- DNA N/A
- EPS Growth
- SAGE N/A
- DNA N/A
- EPS
- SAGE N/A
- DNA N/A
- Revenue
- SAGE $41,243,000.00
- DNA $227,043,000.00
- Revenue This Year
- SAGE $100.39
- DNA N/A
- Revenue Next Year
- SAGE $70.86
- DNA $19.36
- P/E Ratio
- SAGE N/A
- DNA N/A
- Revenue Growth
- SAGE N/A
- DNA N/A
- 52 Week Low
- SAGE $4.62
- DNA $5.26
- 52 Week High
- SAGE $17.51
- DNA $47.60
- Technical
- Relative Strength Index (RSI)
- SAGE 40.58
- DNA 32.79
- Support Level
- SAGE $7.99
- DNA $5.35
- Resistance Level
- SAGE $7.97
- DNA $6.20
- Average True Range (ATR)
- SAGE 0.31
- DNA 0.53
- MACD
- SAGE -0.10
- DNA 0.01
- Stochastic Oscillator
- SAGE 1.37
- DNA 12.92
About SAGE Sage Therapeutics Inc.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
About DNA Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering and BiosecurityThe majority of revenue in the company comes from the Biosecurity segment, which charges fees for data analytics and services.